Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Cited by (388)

Items 301–388 of 388

1. Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
   Zhao, Fei, Evans, Kathy, Xiao, Christine, DeVito, Nicholas, Theivanthiran, Balamayooran, Holtzhausen, Alisha, Siska, Peter J., Blobe, Gerard C., Hanks, Brent A. · 2018 · Cancer Immunology Research
2. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity
   Yano, Hiroshi, Andrews, Lawrence P., Workman, Creg J., Vignali, Dario A. A. · 2019 · Immunology
3. Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
   Zhu, Bo, Tang, Liming, Chen, Shuyang, Yin, Chengqian, Peng, Shiguang, Li, Xin, Liu, Tongzheng, Liu, Wei, Han, Changpeng, Stawski, Lukasz et al. · 2018 · Oncogene
4. Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
   Torino, Francesco, Barnabei, Agnese, Paragliola, Rosamaria, Baldelli, Roberto, Appetecchia, Marialuisa, Corsello, Salvatore Maria · 2013 · Thyroid®
5. Hypoxia signaling in cancer: Implications for therapeutic interventions
   Zhuang, Yan, Liu, Kua, He, Qinyu, Gu, Xiaosong, Jiang, Chunping, Wu, Junhua · 2023 · MedComm
6. Circulating tumour DNA (CtDNA) as a liquid biopsy for melanoma
   Calapre, Leslie, Warburton, Lydia, Millward, Michael, Ziman, Mel, Gray, Elin S. · 2017 · Cancer Letters
7. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
   Rekhtman, Natasha, Ang, Daphne C, Riely, Gregory J, Ladanyi, Marc, Moreira, Andre L · 2013 · Modern Pathology
8. Hyponatraemia secondary to nivolumab-induced primary adrenal failure
   Trainer, Harris, Hulse, Paul, Higham, Claire E, Trainer, Peter, Lorigan, Paul · 2016 · Endocrinology, Diabetes & Metabolism Case Reports
9. Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
   Shi, Lewis Zhichang, Fu, Tihui, Guan, Baoxiang, Chen, Jianfeng, Blando, Jorge M., Allison, James P., Xiong, Liangwen, Subudhi, Sumit K., Gao, Jianjun, Sharma, Padmanee · 2016 · Nature Communications
10. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2
    Chaib, Selim, López-Domínguez, José Alberto, Lalinde-Gutiérrez, Marta, Prats, Neus, Marin, Ines, Boix, Olga, García-Garijo, Andrea, Meyer, Kathleen, Muñoz, María Isabel, Aguilera, Mònica et al. · 2024 · Nature Cancer
11. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
    Salman, Shaima, Meyers, David J., Wicks, Elizabeth E., Lee, Sophia N., Datan, Emmanuel, Thomas, Aline M., Anders, Nicole M., Hwang, Yousang, Lyu, Yajing, Yang, Yongkang et al. · 2022 · Journal of Clinical Investigation
12. PD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
    Scheel, Andreas H., Ansén, Sascha, Schultheis, Anne M., Scheffler, Matthias, Fischer, Rieke N., Michels, Sebastian, Hellmich, Martin, George, Julie, Zander, Thomas, Brockmann, Michael et al. · 2016 · OncoImmunology
13. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort
    Newsome, Rachel C., Gharaibeh, Raad Z., Pierce, Christine M., da Silva, Wildson Vieira, Paul, Shirlene, Hogue, Stephanie R., Yu, Qin, Antonia, Scott, Conejo-Garcia, Jose R., Robinson, Lary A. et al. · 2022 · Genome Medicine
14. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
15. The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
    Paucek, Richard D., Baltimore, David, Li, Guideng · 2019 · Trends in Immunology
16. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
    Lee, Pei-Chang, Chao, Yee, Chen, Ming-Huang, Lan, Keng-Hsin, Lee, Chieh-Ju, Lee, I-Cheng, Chen, San-Chi, Hou, Ming-Chih, Huang, Yi-Hsiang · 2020 · Cancers
17. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy
    Wang, Huan Bin, Yao, Han, Li, Chu Shu, Liang, Lun Xi, Zhang, Yao, Chen, Ying Xuan, Fang, Jing‐Yuan, Xu, Jie · 2017 · Journal of Digestive Diseases
18. Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy
    Chen, Qian, Xu, Ligeng, Chen, Jiawen, Yang, Zhijuan, Liang, Chao, Yang, Yu, Liu, Zhuang · 2017 · Biomaterials
19. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
    Overacre-Delgoffe, Abigail E., Vignali, Dario A.A. · 2018 · Cancer Immunology Research
20. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency
    Davies, Helen, Morganella, Sandro, Purdie, Colin A., Jang, Se Jin, Borgen, Elin, Russnes, Hege, Glodzik, Dominik, Zou, Xueqing, Viari, Alain, Richardson, Andrea L. et al. · 2017 · Cancer Research
21. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
    Johnson, Douglas B., Friedman, Debra L., Berry, Elizabeth, Decker, Ilka, Ye, Fei, Zhao, Shilin, Morgans, Alicia K., Puzanov, Igor, Sosman, Jeffrey A., Lovly, Christine M. · 2015 · Cancer Immunology Research
22. Clinical impact of probiotics on the efficacy of <scp>anti‐PD</scp>‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting
    Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya‐Kawano, Yuko, Otsubo, Kohei et al. · 2021 · International Journal of Cancer
23. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses
    Lo, Jennifer A., Kawakubo, Masayoshi, Juneja, Vikram R., Su, Mack Y., Erlich, Tal H., LaFleur, Martin W., Kemeny, Lajos V., Rashid, Mamunur, Malehmir, Mohsen, Rabi, S. Alireza et al. · 2021 · Science Translational Medicine
24. Targeting LKB1 in Cancer – Exposing and Exploiting Vulnerabilities
    Momcilovic, M, Shackelford, D B · 2015 · British Journal of Cancer
25. Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment
    Vilgelm, Anna E., Johnson, C. Andrew, Prasad, Nripesh, Yang, Jinming, Chen, Sheau-Chiann, Ayers, Gregory D., Pawlikowski, Jeff S., Raman, Dayanidhi, Sosman, Jeffrey A., Kelley, Mark et al. · 2016 · JNCI Journal of the National Cancer Institute
26. Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer
    Guo, Xinyi, Nie, Hu, Zhang, Wenwen, Li, Jiesheng, Ge, Jing, Xie, Bowen, Hu, Wenbo, Zhu, Yicheng, Zhong, Na, Zhang, Xinmei et al. · 2025 · Cancer Cell
27. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study
    She, Yunlang, He, Bingxi, Wang, Fang, Zhong, Yifan, Wang, Tingting, Liu, Zhenchuan, Yang, Minglei, Yu, Bentong, Deng, Jiajun, Sun, Xiwen et al. · 2022 · eBioMedicine
28. Product review: Avelumab, an anti-PD-L1 antibody
    Collins, Julie M., Gulley, James L. · 2019 · Human Vaccines &amp; Immunotherapeutics
29. Melanoma and microbiota: Current understanding and future directions
    Routy, Bertrand, Jackson, Tanisha, Mählmann, Laura, Baumgartner, Christina K., Blaser, Martin, Byrd, Allyson, Corvaia, Nathalie, Couts, Kasey, Davar, Diwakar, Derosa, Lisa et al. · 2024 · Cancer Cell
30. Immunotherapy via PD-L1–presenting biomaterials leads to long-term islet graft survival
    Coronel, María M., Martin, Karen E., Hunckler, Michael D., Barber, Graham, O’Neill, Eric B., Medina, Juan D., Opri, Enrico, McClain, Claire A., Batra, Lalit, Weaver, Jessica D. et al. · 2020 · Science Advances
31. High intratumoral CD8 ⁺ T‐cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy
    Yang, Yuanquan, Attwood, Kristopher, Bshara, Wiam, Mohler, James L., Guru, Khurshid, Xu, Bo, Kalinski, Pawel, Chatta, Gurkamal · 2021 · The Prostate
32. Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
    Leto, Simonetta M., Trusolino, Livio · 2014 · Journal of Molecular Medicine
33. Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma
    Arakawa, Akiko, Vollmer, Sigrid, Tietze, Julia, Galinski, Adrian, Heppt, Markus V., Bürdek, Maja, Berking, Carola, Prinz, Jörg C. · 2019 · Frontiers in Immunology
34. Kras and tumor immunity: friend or foe?
    Cullis, Jane, Das, Shipra, Bar-Sagi, Dafna · 2018 · Cold Spring Harbor Perspectives in Medicine
35. Haematological malignancies: at the forefront of immunotherapeutic innovation
    Bachireddy, Pavan, Burkhardt, Ute E., Rajasagi, Mohini, Wu, Catherine J. · 2015 · Nature Reviews Cancer
36. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
    Shi, Congqi, Qin, Kaiyu, Lin, Anqi, Jiang, Aimin, Cheng, Quan, Liu, Zaoqu, Zhang, Jian, Luo, Peng · 2022 · Journal of Experimental &amp; Clinical Cancer Research
37. Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
    Passiglia, Francesco, Cappuzzo, Federico, Alabiso, Oscar, Bettini, Anna Cecilia, Bidoli, Paolo, Chiari, Rita, Defferrari, Carlotta, Delmonte, Angelo, Finocchiaro, Giovanna, Francini, Guido et al. · 2019 · British Journal of Cancer
38. Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
    Nonomura, Yumi, Otsuka, Atsushi, Nakashima, Chisa, Seidel, Judith A., Kitoh, Akihiko, Dainichi, Teruki, Nakajima, Saeko, Sawada, Yu, Matsushita, Shigeto, Aoki, Megumi et al. · 2016 · OncoImmunology
39. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma
    Suo, Aleksi, Chan, Yin, Beaulieu, Carissa, Kong, Shiying, Cheung, Winson Y., Monzon, Jose G., Smylie, Michael, Walker, John, Morris, Don, Cheng, Tina · 2020 · The Oncologist
40. Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
    Peyraud, F., Guégan, J.-P., Bodet, D., Nafia, I., Fontan, L., Auzanneau, C., Cousin, S., Roubaud, G., Cabart, M., Chomy, F. et al. · 2022 · Annals of Oncology
41. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
    Davis, Kara L., Fox, Elizabeth, Isikwei, Emasenyie, Reid, Joel M., Liu, Xiaowei, Minard, Charles G., Voss, Stephan, Berg, Stacey L., Weigel, Brenda J., Mackall, Crystal L. · 2022 · Clinical Cancer Research
42. Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors
    Lu, Jia-Cheng, Zeng, Hai-Ying, Sun, Qi-Man, Meng, Qing-Nan, Huang, Xiao-Yong, Zhang, Peng-Fei, Yang, Xuan, Peng, Rui, Gao, Chao, Wei, Chuan-Yuan et al. · 2019 · Theranostics
43. <i>Faecalibacterium prausnitzii</i> strain EXL01 boosts efficacy of immune checkpoint inhibitors
    Bredon, Marius, Danne, Camille, Pham, Hang Phuong, Ruffié, Pauline, Bessede, Alban, Rolhion, Nathalie, Creusot, Laura, Brot, Loic, Alonso, Iria, Langella, Philippe et al. · 2024 · OncoImmunology
44. Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials
    Kanjanapan, Y., Day, D., Butler, M.O., Wang, L., Joshua, A.M., Hogg, D., Leighl, N.B., Razak, A.R. Abdul, Hansen, A.R., Boujos, S. et al. · 2019 · European Journal of Cancer
45. Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS–RAF</i> Mutations
    Zimmer, Lisa, Barlesi, Fabrice, Martinez-Garcia, Maria, Dieras, Veronique, Schellens, Jan H.M., Spano, Jean-Philippe, Middleton, Mark R., Calvo, Emiliano, Paz-Ares, Luiz, Larkin, James et al. · 2014 · Clinical Cancer Research
46. Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
    Honda, Yuki, Otsuka, Atsushi, Ono, Sachiko, Yamamoto, Yosuke, Seidel, Judith A., Morita, Satoshi, Hirata, Masahiro, Kataoka, Tatsuki R., Takenouchi, Tatsuya, Fujii, Kazuyasu et al. · 2017 · OncoImmunology
47. Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28
    Zhang, Chaoxu, Fan, Yibo, Che, Xiaofang, Zhang, Min, Li, Zhi, Li, Ce, Wang, Shuo, Wen, Ti, Hou, Kezuo, Shao, Xinye et al. · 2020 · Frontiers in Oncology
48. PD-1 coinhibitory signals: the link between pathogenesis and protection
    Kulpa, Deanna A., Lawani, Mariam, Cooper, Anthony, Peretz, Yoav, Ahlers, Jeff, Sékaly, Rafick-Pierre · 2013 · Seminars in Immunology
49. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures
    Gestermann, Nicolas, Saugy, Damien, Martignier, Christophe, Tillé, Laure, Fuertes Marraco, Silvia A., Zettl, Markus, Tirapu, Iñigo, Speiser, Daniel E., Verdeil, Grégory · 2020 · OncoImmunology
50. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma
    Woods, David M., Ramakrishnan, Rupal, Laino, Andressa S., Berglund, Anders, Walton, Kelly, Betts, Brian C., Weber, Jeffrey S. · 2018 · Clinical Cancer Research
51. Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
    Fan, Zhenzhen, Tian, Yahui, Chen, Zhipeng, Liu, Lu, Zhou, Qian, He, Jingjing, Coleman, James, Dong, Changjiang, Li, Nan, Huang, Junqi et al. · 2020 · EMBO Molecular Medicine
52. Vaccine therapy for pancreatic cancer
    Salman, Bulent, Zhou, Donger, Jaffee, Elizabeth M, Edil, Barish H, Zheng, Lei · 2013 · OncoImmunology
53. Considerations for successful cancer immunotherapy in aged hosts
    Hurez, V, Padrón, Á S, Svatek, R S, Curiel, T J · 2016 · Clinical and Experimental Immunology
54. PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation
    Shimizu, Kenji, Sugiura, Daisuke, Okazaki, Il-mi, Maruhashi, Takumi, Takegami, Yujiro, Cheng, Chaoyang, Ozaki, Soichi, Okazaki, Taku · 2020 · Molecular Cell
55. Cell Fate Reprogramming in the Era of Cancer Immunotherapy
    Zimmermannova, Olga, Caiado, Inês, Ferreira, Alexandra G., Pereira, Carlos-Filipe · 2021 · Frontiers in Immunology
56. ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy
    Li, Chunyang, Li, Weiyun, Xiao, Jun, Jiao, Shaozhuo, Teng, Fei, Xue, Shengjie, Zhang, Chi, Sheng, Chun, Leng, Qibin, Rudd, Christopher E et al. · 2015 · EMBO Molecular Medicine
57. Checkpoint immunotherapy in pediatrics: here, gone, and back again
    Long, Adrienne H., Morgenstern, Daniel A., Leruste, Amaury, Bourdeaut, Franck, Davis, Kara L. · 2022 · American Society of Clinical Oncology Educational Book
58. HDACs and the epigenetic plasticity of cancer cells: target the complexity
    Brancolini, Claudio, Gagliano, Teresa, Minisini, Martina · 2022 · Pharmacology &amp; Therapeutics
59. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report
    Zhu, Xiao, McDowell, Michael M., Newman, William C., Mason, Gary E., Greene, Stephanie, Tamber, Mandeep S. · 2017 · Journal of Neurosurgery: Pediatrics
60. Pegylated <scp>IL</scp>‐10 induces cancer immunity: The surprising role of IL‐10 as a potent inducer of IFN‐γ‐mediated CD8⁺ T cell cytotoxicity
    Mumm, John B., Oft, Martin · 2013 · BioEssays
61. Biomarkers for Response to Immune Checkpoint Blockade
    Ganesan, Shridar, Mehnert, Janice · 2020 · Annual Review of Cancer Biology
62. New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses
    Kamrani, Amin, Nasiri, Hadi, Hassanzadeh, Ali, Ahmadian Heris, Javad, Mohammadinasab, Reza, Sadeghvand, Shahram, Sadeghi, Mohammadreza, Valedkarimi, Zahra, Hosseinzadeh, Ramin, Shomali, Navid et al. · 2024 · Cell Communication and Signaling
63. PD‐L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation
    Rodić, Nemanja, Anders, Robert A., Eshleman, James R., Lin, Ming-Tseh, Xu, Haiying, Kim, Jung H., Beierl, Katie, Chen, Shuming, Luber, Brandon S., Wang, Hao et al. · 2015 · Cancer Immunology Research
64. p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
    Hardwick, Nicola R., Carroll, Mary, Kaltcheva, Teodora, Qian, Dajun, Lim, Dean, Leong, Lucille, Chu, Peiguo, Kim, Joseph, Chao, Joseph, Fakih, Marwan et al. · 2014 · Clinical Cancer Research
65. A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors
    Abdel-Rahman, Omar, Fouad, Mona · 2016 · Immunotherapy
66. Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer
    Yu, Irene, Dakwar, Anthony, Takabe, Kazuaki · 2023 · Cells
67. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice
    Yassin, Mohammad, Sadowska, Zuzanna, Djurhuus, Ditte, Nielsen, Brian, Tougaard, Peter, Olsen, Jørgen, Pedersen, Anders Elm · 2019 · Immunology
68. Colorectal Cancer Immunotherapy: State of the Art and Future Directions
    Cornista, Alyssa Mauri, Giolito, Maria Virginia, Baker, Kristi, Hazime, Hajar, Dufait, Inès, Datta, Jashodeep, Khumukcham, Saratchandra Singh, De Ridder, Mark, Roper, Jatin, Abreu, Maria T. et al. · 2023 · Gastro Hep Advances
69. Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics
    Frazier, Kendall S., Engelhardt, Jeffery A., Fant, Pierluigi, Guionaud, Silvia, Henry, Scott P., Leach, Michael W., Louden, Calvert, Scicchitano, Marshall S., Weaver, James L., Zabka, Tanja S. · 2015 · Toxicologic Pathology
70. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control
    Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael · 2019 · Cancer Medicine
71. Learning from the Proteasome How To Fine-Tune Cancer Immunotherapy
    Vigneron, Nathalie, Abi Habib, Joanna, Van den Eynde, Benoit J. · 2017 · Trends in Cancer
72. Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes
    Connell, C.M., Raby, S., Beh, I., Flint, T.R., Williams, E.H., Fearon, D.T., Jodrell, D.I., Janowitz, T. · 2017 · Annals of Oncology
73. A clinically acceptable strategy for sensitizing anti-PD-1 treatment by hypoxia relief
    Jiang, Mengshi, Qin, Bing, Luo, Lihua, Li, Xiang, Shi, Yingying, Zhang, Junlei, Luo, Zhenyu, Zhu, Chunqi, Guan, Guannan, Du, Yongzhong et al. · 2021 · Journal of Controlled Release
74. Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer
    Snahnicanova, Zuzana, Kasubova, Ivana, Kalman, Michal, Grendar, Marian, Mikolajcik, Peter, Gabonova, Eva, Laca, Ludovit, Caprnda, Martin, Rodrigo, Luis, Ciccocioppo, Rachele et al. · 2020 · Clinical and Experimental Medicine
75. Single-Cell RNA Sequencing for Studying Human Cancers
    Aran, Dvir · 2023 · Annual Review of Biomedical Data Science
76. Obesity and Cancer Immunotherapy Toxicity
    Mirsoian, Annie, Murphy, William J · 2015 · Immunotherapy
77. Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea
    Huang, Mao-Hong, Zhang, Xiao-Bin, Wang, Hui-Ling, Li, Liu-Xia, Zeng, Yi-Ming, Wang, Miao, Zeng, Hui-Qing · 2019 · Annals of Translational Medicine
78. Neoadjuvant <i>In Situ</i> Immunomodulation Enhances Systemic Antitumor Immunity against Highly Metastatic Tumors
    Oba, Takaaki, Kajihara, Ryutaro, Yokoi, Toshihiro, Repasky, Elizabeth A., Ito, Fumito · 2021 · Cancer Research
79. Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
    Li, Zhiyang, Wu, Xin, Zhao, Yanjie, Xiao, Yinan, Zhao, Yunuo, Zhang, Ting, Li, Hui, Sha, Fushen, Wang, Yating, Deng, Lei et al. · 2021 · MedComm
80. Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice
    Sekido, Katsuhisa, Tomihara, Kei, Tachinami, Hidetake, Heshiki, Wataru, Sakurai, Kotaro, Moniruzzaman, Rohan, Imaue, Shuichi, Fujiwara, Kumiko, Noguchi, Makoto · 2019 · Oral Oncology
81. Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies
    Weide, Benjamin, Di Giacomo, Anna Maria, Fonsatti, Ester, Zitvogel, Laurence · 2015 · Seminars in Oncology
82. Anti-PD-1 Antibody Therapy Induces Hashimoto’s Disease with an Increase in Peripheral Blood Follicular Helper T Cells
    Torimoto, Keiichi, Okada, Yosuke, Nakayamada, Shingo, Kubo, Satoshi, Tanaka, Yoshiya · 2017 · Thyroid
83. HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients
    Ishida, Yoshihiro, Otsuka, Atsushi, Tanaka, Hidenori, Levesque, Mitchell P., Dummer, Reinhard, Kabashima, Kenji · 2017 · Journal of Investigative Dermatology
84. The biology of combination immunotherapy in recurrent metastatic head and neck cancer
    Yuan, Xun, Yi, Ming, Zhang, Wei, Xu, Linping, Chu, Qian, Luo, Suxia, Wu, Kongming · 2021 · The International Journal of Biochemistry &amp; Cell Biology
85. A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research
    Guedes, Jéssica, Woldmar, Nicole, Szasz, A. Marcell, Wieslander, Elisabet, Pawłowski, Krysztof, Horvatovich, Peter, Malm, Johan, Szadai, Leticia, Németh, István Balázs, Marko-Varga, György et al. · 2025 · Journal of Proteomics
86. Towards personalized medicine in sepsis: quest for Shangri-La?
    Sen, Ayan, Yende, Sachin · 2013 · Critical Care
87. Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets
    Wang, Yungang, Deng, Shouyan, Xu, Jie · 2020 · Cancer Biology and Medicine
88. The role of systemic and targeted therapies in brain metastases
    Franceschi, Enrico, Bartolotti, Marco, Poggi, Rosalba, Battista, Monica Di, Palleschi, Dario, Brandes, Alba A · 2014 · Expert Review of Anticancer Therapy